Fridriksdottir Hafrun, Executive VP, Global R&D, sold 933 shares of the Teva Pharmaceutical Industries Limited (NYSE:TEVA) in an exchange that happened on November 30th, 2018. The stock was sold at an average price of $21.76 per share, amounting to a transaction worth $20,304. The sale was made public in a document filed with the SEC. Additionally, EVP, Chief Financial Officer McClellan Michael James sold 346 shares of this stock in a transaction that took place on November 5th, 2018. The stock was sold at an average price of $22.73 per share, for a total exchange amounting to $7,865. After the transaction, the EVP, Chief Financial Officer McClellan Michael James currently holds 11,644 shares of the company’s stock, which is worth approximately $235907.
With this stock price’s latest movement, it is now -21.96% away from its 1-year high and 44.25% higher than its 1-year low price. In the past seven days, the stock price volatility for Teva Pharmaceutical Industries Limited was 3.12%, whereas its volatility in the past 30 days has been 2.88%. This public company’s stock also has a beta score of 0.73. When the beta value is less/more than 1, it can imply that the stock is less/more volatile than the wider stock market – a metric that traders will surely be keeping tabs on.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) most recently published its quarterly earnings results. The firm posted $0.68 earnings per share (EPS) for the three-month period, surpassing analysts’ consensus estimate of $0.54 by $0.14. The publicly-traded organization reported revenue of $4,529.00 million for the quarter, compared to the average analyst forecast calling for $4,533.26 million, which was missing the analyst consensus estimate.
Shares of Teva Pharmaceutical Industries Limited (TEVA) plunged -1.41%, amounting to a loss of -$0.29 per share, to finish the regular trading session at $20.26 on Thursday 12/06/2018. After beginning the session at $20.34, shares of Teva Pharmaceutical Industries Limited reached as high as $20.34 during the day, while hitting a 1-day low of $19.42. Trade volume reached 17,199,668 shares against this stock’s average daily volume of 11.36M shares, with a total float of 979.12M. As a consequence of the price decrease, Teva Pharmaceutical Industries Limited now has a current market value of 20.78B.
Discovery, Inc. (NASDAQ:DISCA) added 4.18% to its trading price by the close of the most recent session, jumping from its previous closing price of $27.98 to $29.15. This stock decreased in value by -6.90% during the last 7-day period, and experienced a loss of -12.20% over the past 30-day period. In the past three months, this stock’s price grew by 5.54% , and added 28.02% to its price during the last six months of trading. DISCA demonstrated a yearly price gain of 46.78% , while its year-to-date (YTD) price performance has been up 30.25% . This stock’s price changed by +11.94% compared to its 90-day low, and moved down -16.45% comparing to its 90-day high price.
Have a quick look on short, medium and long-term indicators. According to the Composite Indicator, Trendspotter rated the DISCA stock as “Sell”. In the short-term, Discovery, Inc. (DISCA) has a 20-day average volume of 4,877,760 shares and short-term indicators sets the DISCA stock as “ 80% Sell ” on average basis. In the medium-term, DISCA stock has a 50-Day average volume of 4,566,910 shares and medium-term indicators gave the average rating of “ 50% Sell ”, while in the long-term period the FB stock has a 100-Day average volume of 4,124,006 shares. On average, long-term indicators rated the stock as “33% Sell ”. The overall picture from all short, medium and long-term indicators sets the DISCA stock as “64% Sell ” on average basis.
Recently, multiple brokerages have sent out reports on DISCA. Pivotal Research Group, for example, Upgrade its rating on shares of Discovery, Inc. from “Sell ” to a “ Hold”, while setting a $27 price target on shares of the company’s stock, according to a research note from Thursday December 6th, 2018. Imperial Capital Reiterated their target price for this stock from $37 to $31, while giving the stock a “In-line” rating, as stated in a research report from Tuesday, December 4th, 2018. Pivotal Research Group, on the other hand, Reiterated a “Sell” rating on this stock, while posting a $27 price target on shares of this company’s stock in a research note dated Friday, November 9th, 2018.
In other news related to Discovery, Inc. stock, 0.52% shares of DISCA held by institutions. The total number of institutions who held the DISCA shares was 10, according to most recent SEC filling. During the past quarter, total 33,718 shares held by institutions with the net change of -92 shares. In the meantime, 1 new institutions bought the shares of Discovery, Inc. for the first time and 0 institutions sold all their holdings in the company’s common stock. 1 institutions increased their investment in the DISCA stock and 2 institutions decreased their investment in the Discovery, Inc. (DISCA)’s stock during the last quarter.